Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality ...

A real-world study of patients with Clostridioides difficile infection (CDI) in Australia over 10 years shows that fecal ...

It may take up to two weeks for a bout of C. diff to respond to treatment and for diarrhea to clear up. In the interim, while ...

There are currently no C. difficile vaccines available, and the main treatment for the infection is a lengthy course of ...

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a ...

The team developed the treatment for Clostridioides difficile, or C. difficile, a bacterium that can cause severe diarrhea, abdominal pain and colon inflammation. C. difficile can overgrow when ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Clostridium difficile infection (CDI ... Although metronidazole and vancomycin are and have been the mainstay treatment options for CDI, there are some unmet medical and therapeutical needs.

Acurx Pharmaceuticals Inc (ACXP) progresses with phase 3 trials for Ibezapolstat while navigating financial hurdles and seeking strategic partnerships.